Abstract
Wrapping designs have limitations arising from similarities in the biomolecular interfaces of on-target and off-target homologous proteins and also from the highly diverse cellular contexts wherein a protein may constitute a desirable or undesirable target. While dehydron wrapping enables the control of specificity, it may not be able to exclude every single toxicity-related target, especially if the latter shares with the therapeutically relevant targets a similar dehydron pattern in the drug-binding region. In such circumstances, we may need to resort to a multicomponent therapy where one drug acts synergistically with the other while selectively antagonizing it in the specific cellular context where the action of the first drug promotes toxicity. This chapter explores these a-priori therapeutic possibilities. As previously described, due to their ability to interfere with signal transduction events controlling cell proliferation and fate, kinase inhibitors hold promise as anticancer agents. Nevertheless, the functional role of a kinase depends on the cellular context and hence kinase inhibition in an off-target cell may lead to undesired side effects. Motivated by these observations, we explore a mode of “therapeutic editing” where one drug—the editor—suppresses the side effect promoted by the primary drug as it impacts off-target cells. Editor and primary drug have overlapping therapeutic impact, while the editor suppresses the downstream propagation of toxicity-related signaling triggered by the primary drug in an off-target cellular context.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12:1443–1455
Schmidinger M, Zielinski CC, Vogl UM et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204–5212
Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812
Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475–485
Force T, Krause D, van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332–344
Force T, Kerkela R (2008) Cardiotoxicity of the new cancer therapeutics—mechanisms of, and approaches to, the problem. Drug Discov Today 13:778–784
Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–916
Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitnib. Lancet 370:2011–2019
Fernández A, Crespo A, Tiwari A (2009) Is there a case for selectively promiscuous anticancer drugs? Drug Discov Today 14:1–5
Zhang X, Crespo A, Fernández A (2008) Turning promiscuous kinase inhibitors into safer drugs. Trends Biotech 26:295–301
Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296–313
Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782–1788
Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G (2007) An anticancer c-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117:4044–4054
Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6:202–209
Torchilin VP (2006) Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532–1555
Langer R (2001) Drug delivery: drugs on target. Science 293:58–59
Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818–1822
Deninger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640–2653
Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer drugs. Nat Rev Drug Discov 5:649–659
Keith CT, Borisky AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4:71–78
Zimmermann GR, Lehar J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12:34–42
Verweij J, Casali P, Kotasek D et al (2007) Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 43:974–978
Atallah E, Durand JB, Kantarjian H, Cortes J (2007) Congestive heart failure is a rare event in patients receiving imatinib. Blood 110:1233–1237
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134
O’Neill E, Rushworth L, Baccarini M, Kolch W (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product raf-1. Science 306:2267–2270
Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290
Chen J, Zhang X, Fernández A (2007) Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics 23:563–572
Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734–745
O’Neill EE, Matallanas D, Kolch W (2005) Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res 65:5485–5487
Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotech 26:127–132
Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P (2006) Dasatinib. Nat Rev Drug Discov 5:717–718
Fernández A, Sessel S (2009) Selective antagonism of anticancer drugs for side effect removal. Trends Pharmacol Sci 30:403–410
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Fernández Stigliano, A. (2015). Wrapping Drug Combinations for Therapeutic Editing of Side Effects: Systems Biology Meets Wrapping Technology. In: Biomolecular Interfaces. Springer, Cham. https://doi.org/10.1007/978-3-319-16850-0_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-16850-0_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16849-4
Online ISBN: 978-3-319-16850-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)